ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
Healthcare
$0.97 -2.12%
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
52W Low $0.40High $2.66
Volume 0.56M
Average 1.07M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$84.14M
FY 2025 · Annual
Investing Cash Flow
$82.59M
FY 2025 · Annual
-4.3% YoYFinancing Cash Flow
$362,000.00
FY 2025 · Annual
-98.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.46M) | (123.48M) | (160.81M) | (134.85M) | (101.7M) |
| Depreciation & Amortization | 51K | 342K | 836K | 872K | 706K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.91M | 23.84M | 26.27M | 27.09M | 12.58M |
| Change in Working Capital | (4.03M) | 9.85M | 8.3M | (12.43M) | 336K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.29M | 4.51M | 458K | (4.02M) | 421K |
| Other Working Capital | (7.32M) | 5.34M | 7.84M | (8.41M) | (85K) |
| Other Non-Cash Items | 5.42M | 228K | (4.97M) | (2.6M) | 3.93M |
| Operating Cash Flow | (68.1M) | (89.22M) | (130.36M) | (121.91M) | (84.14M) |
| Capital Expenditures | (4.92M) | (1.43M) | (1.27M) | (447K) | (212K) |
| Acquisitions (Net) | 0 | 233.99K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (376.79M) | (246.63M) | (107.41M) | (51.59M) |
| Sales of Investments | 0 | 142.8M | 292.56M | 194.11M | 134.39M |
| Other Investing Activities | 0 | (233.99K) | 0 | 0 | 0 |
| Investing Cash Flow | (4.92M) | (235.42M) | 44.66M | 86.26M | 82.59M |
| Debt Repayment | (281K) | 9.61M | (388K) | (827K) | (1.36M) |
| Common Stock Issued | 2.75M | 903K | 58.89M | 31.64M | 1.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (655K) | 792K | 0 | 0 |
| Financing Cash Flow | 2.47M | 9.86M | 59.29M | 30.82M | 362K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (70.55M) | (314.78M) | (26.42M) | (4.84M) | (1.19M) |
| Free Cash Flow | (73.02M) | (90.65M) | (131.64M) | (122.36M) | (84.35M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$101.7M
+ D&A$706.0K
+ Stock-Based Comp$12.6M
+ Deferred Tax$0
+ Working Capital$336.0K
+ Other Non-Cash$3.9M
= Operating Cash Flow-$84.1M
- Capex-$212.0K
= Free Cash Flow-$84.4M
Analysis
FY2025 free cash flow is -$84.4M. FCF conversion is 82.9% of net income. Operating cash flow was -$84.1M, with capex of -$212.0K. The largest bridge item is Stock-Based Comp at $12.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Oct 16, 2026 | |
| 8-K | Current report | Oct 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
Does ALXO generate free cash flow?
ALX Oncology Holdings Inc. (ALXO) generated -$84.35M of free cash flow in fiscal 2025.
How much operating cash flow does ALXO produce?
Operating cash flow was -$84.14M, before capital expenditures of $212,000.00.
Continue the stock analysis
Jump to another research area for this company.